Anavex Life Sciences

Yahoo Finance • 3 days ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story

Yahoo Finance • 11 days ago

Why Anavex Is Rising In Pre-market?

(RTTNews) - Anavex Life Sciences (AVXL) announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study... Full story

Yahoo Finance • 11 days ago

Anavex rises after mid-stage trial data for schizophrenia candidate

[Crumpled piece of paper with word Schizophrenia on torn white paper pieces background.] Anavex Life Sciences (NASDAQ:AVXL [https://seekingalpha.com/symbol/AVXL]) traded higher in the premarket on Thursday after the New York-based biotech... Full story

Yahoo Finance • 11 days ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, ena... Full story

Yahoo Finance • last month

Notable Wednesday Option Activity: CLSK, BKD, AVXL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CleanSpark Inc (Symbol: CLSK), where a total volume of 108,050 contracts has been traded thus far today, a contract volum... Full story

Yahoo Finance • last month

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward norma... Full story

Yahoo Finance • 2 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story

Yahoo Finance • 2 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company... Full story

Yahoo Finance • 2 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Company to host a webcasttoday at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * Cardinal Health (CAH [https://seekingalpha.com/symbol/CAH]) * Circle Internet Group (CRCL [https://seekingalpha.co... Full story

Yahoo Finance • 2 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story

Yahoo Finance • 2 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P < 0.0001) Restoring impaired autophagy as ea... Full story

Yahoo Finance • 3 months ago

Eli Lilly, GE Vernova Surge Among Wednesday's Market Cap Stock Movers

Wednesday’s market has seen significant activity, with stocks like Eli Lilly And Co (NYSE:LLY) and GE Vernova LLC (GEV) experiencing notable increases, while Fiserv Inc (NYSE:FI) (FISV) faced a sharp decline. These movements reflect a... Full story

Yahoo Finance • 3 months ago

Anavex Life Sciences extends CEO and principal financial officer contracts

Anavex Life Sciences Corp. (NASDAQ:AVXL), a biotechnology company with a strong financial position and current ratio of 6.74x, announced Thursday that it has amended the employment agreements of its Chief Executive Officer and Principal F... Full story

Yahoo Finance • 4 months ago

ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm

PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex”) on behalf of the... Full story

Yahoo Finance • 5 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's... Full story

Yahoo Finance • 5 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing... Full story

Yahoo Finance • 5 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's... Full story

Yahoo Finance • 6 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson... Full story

Yahoo Finance • 6 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson... Full story